Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 8, 2020
Daily News
July 8, 2020
- Kyoto University, NIBIOHN to Join Forces on Drug Discovery
July 8, 2020
- LDP Lawmakers’ League to Launch Group to Protect People against HPV
July 8, 2020
- GSK in Quest for Best COVID-19 Vaccine, Not the First: Japan Chief Lirette
July 8, 2020
- Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
- Sales Rep Promotions in May Tank 67% YOY: Intage
July 8, 2020
- Japan Ethical Drug Sales Slide 12.0% in May: Crecon
July 8, 2020
- EU Regulators Accept Enhertu for Accelerated Review for HER2-Positive Breast Cancer
July 8, 2020
- Sunovion’s Bipolar Depression Med Fails to Show Statistically Significant Improvement in PII
July 8, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…